Welcome to our dedicated page for Nutriband news (Ticker: NTRBW), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
Nutriband Inc. (NTRBW) delivers innovative transdermal solutions addressing critical pharmaceutical safety challenges through its proprietary AVERSA® technology. This dedicated news hub provides investors and industry stakeholders with essential updates about regulatory progress, product development milestones, and strategic partnerships.
Access real-time announcements covering clinical trial developments, intellectual property expansions, manufacturing agreements, and consumer product launches. Our curated feed includes earnings reports, FDA submission updates, and analysis of technologies combating opioid misuse through abuse-deterrent systems.
Key focus areas include advancements in transdermal drug delivery systems, international patent grants, and collaborations with industry leaders like Kindeva Drug Delivery. Stay informed about Nutriband's progress in integrating Bitrex®-based safety mechanisms across therapeutic applications while maintaining compliance with global regulatory standards.
Bookmark this page for verified updates about Nutriband's mission to enhance medication safety through cutting-edge transdermal innovations. Monitor critical developments in pharmaceutical abuse prevention and topical delivery systems from a single authoritative source.
Nutriband Inc. (NASDAQ: NTRB) has announced the appointment of World and European Wrestling Gold medalist and Olympic Silver medalist Anastasia Nichita to its Product Advisory Board. The appointment aims to expand the Nutriband Brand and promote its over-the-counter sports and consumer products internationally.
The company, which develops transdermal pharmaceutical products through its subsidiary Pocono Pharma, produces multiple products including AI Tape. This product combines traditional kinesiology tape benefits with soothing and therapeutic ingredients in a proprietary adhesive mix.
Nutriband Inc. (NASDAQ:NTRB) has received a Notice of Allowance from the USPTO for patent application 18/369,241, covering its Aversa™ abuse deterrent technology. This technology is designed to prevent abuse, diversion, misuse, and accidental exposure of drugs with abuse potential in transdermal patches.
The company's lead product, Aversa™ Fentanyl, aims to become the first abuse-deterrent fentanyl transdermal system. The technology utilizes a proprietary aversive agent coating that employs taste aversion to deter oral abuse. The intellectual property is protected by patents in 46 countries, including major markets like the US, Europe, Japan, and China.
According to a market analysis report, Aversa Fentanyl has the potential to achieve peak annual US sales between $80 million to $200 million.
Nutriband (NASDAQ: NTRB) has released its 2024 shareholder letter highlighting significant achievements and 2025 outlook. The company reported record Q3 revenue of $645,796, a 51% year-over-year increase. Key developments include advancing their AVERSA™ Fentanyl product, projected to achieve peak annual U.S. sales of $80-200 million, toward commercialization with partner Kindeva Drug Delivery.
The company secured patent approvals in China and Hong Kong, expanding their intellectual property portfolio to 46 countries. Nutriband raised $8.4 million through a private placement and established an exclusive supplier agreement with Fit For Life Group for major fitness brands. The company plans to submit the New Drug Application (NDA) for AVERSA™ Fentanyl in 2025, with potential regulatory approval expected by year-end.
Nutriband Inc. (NASDAQ:NTRB) has extended its Chinese patent to Macao for its AVERSA™ abuse-deterrent transdermal technology, bringing the total patent coverage to 46 countries and territories. The Macao IP Office assigned patent number J/9010, effective December 17, 2024.
The AVERSA™ technology incorporates aversive agents into transdermal patches to prevent abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. Nutriband is collaborating with Kindeva Drug Delivery to develop AVERSA™ Fentanyl, targeting FDA approval in the first half of 2025. The product has potential peak annual US sales of $80-200 million and aims to be the world's first abuse-deterrent opioid patch.
Nutriband Inc. (NASDAQ:NTRB) reported strong Q3 2024 financial results, with record revenue of $645,796, up 50.94% year-over-year. The company maintains a solid cash position of $5.7 million, with total assets of $12.55 million and stockholders' equity of $11.23 million.
Through its Pocono Pharma subsidiary, Nutriband is expanding its kinesiology tape manufacturing services, with products available in major retailers like Target, Walmart, Walgreens, and CVS. The company continues to progress with AVERSA Fentanyl development, targeting NDA submission in first half of 2025, requiring only a single phase 1 Human Abuse Potential study.
Market analysis projects potential peak annual sales of $80-$200 million for AVERSA Fentanyl and up to $130 million for AVERSA Buprenorphine.
Nutriband Inc. (Nasdaq: NTRB) has announced its participation in the Noble Conference at Florida Atlantic University in Boca Raton on December 3rd-4th, 2024. Company President and Chairman Serguei Melnik will present on December 4th at 1:30 PM in Conference Room 3, focusing on the company's AVERSA technology.
The company specializes in developing transdermal pharmaceutical products, with their flagship product being an abuse-deterrent fentanyl patch incorporating AVERSA™ technology. This innovative technology can be integrated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Presentation details and replay will be available on Channelchek and Youtube after the conference.
Nutriband Inc. (NASDAQ:NTRB) has received a Notice of Publication for its Hong Kong patent protecting AVERSA™ abuse-deterrent transdermal technology. The patent, assigned Publication Number 40085268 B, will be published on December 20, 2024. AVERSA™ technology is now protected by patents in 46 countries, including major markets. The technology incorporates aversive agents into transdermal patches to prevent abuse of drugs like opioids and stimulants. Nutriband is developing AVERSA™ Fentanyl with Kindeva Drug Delivery, potentially becoming the world's first abuse-deterrent opioid patch with projected annual US sales of $80-200 million.
Nutriband (NASDAQ:NTRB) has received full patent issuance from the Chinese National Intellectual Property Administrant (CNIPA) for its 'Abuse and Misuse Deterrent Transdermal System.' The patent (No: ZL 202211158031) supports the company's AVERSA™ technology, developed by 4p Therapeutics, which incorporates taste aversion to prevent abuse of opioid-based transdermal patches. This follows CNIPA's notice of allowance issued in September 2024.
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has received approval from the Costa Rica Ministry of Health for its Mosquito Repellent Patch. The product, designed to reduce mosquito bites and associated health risks, will be exclusively distributed through Farmavision S.A. in Costa Rica. Nutriband plans to expand distribution throughout South and Central America.
The global mosquito repellent market is projected to reach USD $9.30 Billion by 2029 with a 5.23% annual growth rate. The patch contains natural ingredients to mask human odors attractive to insects. It's similar to patches approved in African countries like Ghana, Nigeria, and Ivory Coast for reducing malaria and HIV spread.
Nutriband's subsidiary, Pocono Pharmaceutical, will be the exclusive manufacturer of the product.
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical solutions, is hosting an exclusive live investor webinar and Q&A session on October 17, 2024, at 4:15 p.m. ET. The event, hosted by RedChip Companies, will feature Nutriband Founder and CEO Gareth Sheridan and Founder and President Serguei Melnik, who will discuss the company's current operations and upcoming milestones.
Nutriband is addressing the global opioid crisis with its AVERSA™ abuse-deterrent transdermal technology. The company's lead product, AVERSA™ Fentanyl, is targeting peak annual sales of $80 million to $200 million upon FDA approval. Nutriband is pursuing a streamlined 505(b)(2) NDA regulatory pathway, requiring only a single Phase 1 trial with potential for an expedited six-month FDA review.
FAQ
What is the current stock price of Nutriband (NTRBW)?
